RHL Group’s Novo Nordisk NVO Stock Holding History

RHL Group’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.97K	Buy	+41	New	+$1.76K	﹤0.01%	239

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

RHL Group's NVO Position: Q2 2026 in Review

RHL Group opened a new position in Novo Nordisk (NVO) in Q2 2026: 41 shares worth $1.97K. The stake represents ﹤0.01% of the portfolio and ranks #239 among its holdings.

1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

RHL Group held 41 shares of Novo Nordisk worth $1.97K as of Q2 2026.
Novo Nordisk was a new RHL Group position in Q2 2026.
Novo Nordisk made up ﹤0.01% of RHL Group's portfolio in Q2 2026, its #239 holding.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on RHL Group's 13F filing for Q2 2026, filed 4 Aug 2026.